Last reviewed · How we verify
The Effect of Nifedipine Versus Telmisartan on Prevention of Atrial Fibrillation Recurrence in Hypertensive Patients With Paroxysmal Atrial Fibrillation by Intensive Lower Blood Pressure
Different lowing blood pressure strategies have a different clinical efficacies. Blocking the angiotensin II type 1 receptor (Telmisartan) reduces the incidence of episodes of atrial fibrillation in hypertensive patients with paroxysmal atrial fibrillation during 24 months than 30% compared to Nifedipine( Adalat GITS ). A total of 160 subjects will be included in two study groups. The Group 1 will receive 80-160mg Telmisartan per day, the remaining patients will receive Nifedipine ( Adalat GITS). Follow-up is 24 months. The conventional 12-lead ECG recordings at twice weeks interval and 24hrs holter monitor will determine the cardiac rhythm and asymptomatic episodes of atrial fibrillation. The target of Blood pressure after 3 months is less than 130/80mmHg. Concomitant therapy with B-blocker and acethydrazide are allowed for the target blood pressure during the study.
Details
| Lead sponsor | The Second Affiliated Hospital of Chongqing Medical University |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 160 |
| Start date | 2007-05 |
| Completion | 2011-08 |
Conditions
- Atrial Fibrillation
Interventions
- Nifedipine,
- Telmisartan
Primary outcomes
- Recurrence of Atrial Fibrillation — four years
Recurrence of Atrial Fibrillation ( at least one readable conventional and Holter ECG recording)
Countries
China